|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0015 - 0.0022|
|52 Week Range||0.0013 - 15.0000|
|Beta (3Y Monthly)||1.56|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 14, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.56|
Unique Platform Continues to be Recognized for Distinct Benefits ATLANTA, GA, Oct. 15, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company.
In recent weeks, we have seen a significant rise in the number of our common shares outstanding, which stands at 95,627,584 as of September 30, 2019. This increase is not due to new financings by GeoVax, but rather to the rapid liquidation of convertible preferred stock held by third party investors. Concurrent with this letter, we have filed a Form 8-K with the SEC giving further details. I encourage all shareholders to review this Form 8-K filing. As of September 30, there remain 3,054 shares of unconverted preferred stock ($3,053,782 stated value), which the investors may continue to convert into common stock over the coming weeks. As additional conversions occur, we will provide further updates via SEC filings in order to avoid selective disclosure to individual stockholders.
By John Vandermosten, CFA OTC:GOVX GeoVax Labs, Inc. (OTC:GOVX) filed its second quarter 2019 10-Q and issued the accompanying press release on August 14, 2019 providing an operational and financial update on the company’s performance. During the second quarter GeoVax announced a reverse stock split, presented data from several programs and participated in scientific
ATLANTA, GA / ACCESSWIRE / September 9, 2019 / GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines has historically been associated with the development of vaccines against infectious diseases. The company is now leveraging the knowledge and expertise it has validated in infectious diseases and expanding the applicability of MVA-VLP into immuno-oncology (IO) with highly promising results. GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform.
ATLANTA, GA, Sept. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines, today announced publication of its article entitled “A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge.” The paper appears in the open access journal Pathogens published by MDPI, based in Basel, Switzerland, and can be viewed at https://www.mdpi.com/2076-0817/8/3/133. GeoVax’s Lassa fever vaccine (GEO-LM01) is based on the Company’s novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform, which generates noninfectious VLPs in the individual being vaccinated.
ATLANTA, Aug. 14, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines, today announced its.
Updates Provided on Financial Status and Development Programs ATLANTA, GA, Aug. 02, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company.
ATLANTA, GA, July 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines and immunotherapies, today responded to the World Health Organization’s (WHO) recent declaration of the Ebola outbreak in the Democratic Republic of the Congo (DRC) as a global public health emergency. The Company is offering its novel Ebola preventive vaccine (GEO-EM01), gratis, for public health use, contingent upon WHO or related agencies advancing the vaccine into human clinical evaluation. GeoVax believes its vaccine to be distinctly superior to the experimental vaccine currently in use in failing attempts to contain the epidemic. GeoVax has demonstrated that a single intramuscular (IM) dose of GEO-EM01 provided 100% protection in rhesus macaques challenged with a lethal dose of Ebola virus (EBOV).
Study Data Adds to Similar Efficacy Previously Reported for GeoVax’s Ebola and Lassa Fever Vaccines ATLANTA, GA, July 29, 2019 -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTCQB:.
Presentation Made at the 10th International AIDS Society Conference on HIV Science ATLANTA, GA, July 24, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.
ATLANTA, GA, July 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company specializing in developing human vaccines, announced today that Senior Scientist, Mugdha Vasireddi, PhD, will deliver an oral presentation entitled, A Single Dose of MVA-Based Lassa Virus Vaccine Provides Complete Protection in a Mouse Lethal Challenge Model. The presentation will be given during the Annual Meeting of the American Society for Virology, being held July 20-24 in Minneapolis, Minnesota. In her talk, Dr. Vasireddi will discuss the preclinical efficacy studies of GEO-LM01, a novel vaccine candidate for Lassa fever constructed on an MVA vector expressing two immunogens derived from the Lassa virus.
Since the year began, GeoVax announced collaborations with Enesi Pharma, expanded a collaboration with Leidos, was published in the Atlas of Science and effected a 1:500 reverse stock split. Looking forward to the rest of 2019, we expect a capital raise which will enable the advancement of the HIV and Zika programs, the start of the Phase IIb HVTN efficacy trial and the launch of a Phase I collaboration with AGT for an HIV cure. Grant and collaboration revenues for 1Q:19 were $364,000, representing a 65% increase over 1Q:18 levels.
ATLANTA, May 14, 2019 -- GeoVax Labs, Inc. (OTCQB: GOVXD), a biotechnology company developing human vaccines, today announced its financial results for the three months ended.
1:500 Reverse Split Effective May 2, 2019;Ticker Symbol Changed to GOVXD for 20 Days ATLANTA, GA , May 03, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX) today.
1:500 Reverse Split Effective May 2, 2019;Ticker Symbol Changed to GOVXD for 20 Days ATLANTA, GA, May 03, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX).
ATLANTA, GA, April 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX) today is observing World Malaria Day, an annual international event held on April 25th each year to recognize global efforts to control and ultimately eradicate malaria. GeoVax is commemorating World Malaria Day 2019 by highlighting the efforts of its scientists and collaborators toward the development of a much-needed effective vaccine against this disease. Malaria is a mosquito-borne disease caused by Plasmodium parasites. Nearly half of the world’s population (over 3 billion people) are at risk of malaria infection.
GeoVax Labs, Inc. (GOVX) held its special meeting of stockholders and shareholder vote on April 15, 2019. While many shareholders were concerned that the reverse stock split would lead to poor prospects for future share price performance, the authority was necessary. GeoVax was running out of authorized shares and would not be able to raise funds using equity as there would be insufficient shares to offer for sale.
ATLANTA, March 27, 2019 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced its financial results for the year ended December.
GeoVax (GOVX) recently had its Ebola Vaccine Study published in the Atlas of Science. The article, entitled Single Dose Protection Against Ebola Virus Challenge, highlights the importance of an Ebola vaccine that can be stored at room temperature and minimizes severe adverse events. GeoVax’s GEO-EM01 has demonstrated these characteristics in preclinical studies.
GeoVax Ebola Vaccine Provides Potential for 100% Protection from Single-Dose ATLANTA, GA, March 19, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.
Selection in Two Award Categories follows GeoVax receiving the 2018 Best Biotech Award ATLANTA, GA, March 12, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.
ATLANTA, GA, March 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines and immunotherapies using its novel viral vector platform technology, today provided an update on its progress and development programs. David Dodd, GeoVax President and CEO, commented, “We continue to advance GeoVax’s development programs on multiple fronts with an expanding list of world-class government, academic and corporate collaborators, as further described in this update. Going forward, we will continue to evaluate options to secure the capital needed to proceed with our business plan, especially to advance further programs into human clinical testing.
Supported by Contract from U.S. Agency for International Development (USAID) ATLANTA, GA, March 04, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.
Comments on HHS Initiative “Ending the HIV Epidemic: A Plan for America” ATLANTA, GA, Feb. 14, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology.
Today, individuals and organizations across the country will observe National Black HIV/AIDS Awareness Day. GeoVax is commemorating the day by celebrating the progress toward the development of a vaccine against HIV, recognizing the work yet to be done, and bringing attention to the continued HIV epidemic in the United States and the disproportionate impact of the disease on African-Americans.